div class=trans-pagebuttonPage 1button div class=trans-image a href=https:reader042fdocumentsecreader042viewer20220219055bb0dfc509d3f281368bfeb4html5page1jpg target=_blank amp-img class=trans-thumb alt=Page 1: · Conectivopatías lupus eritematoso Procesos linfoproliferativos Presencia autoanticuerpos 30-70%: Antitiroideos Antinucleares Anti-lgE anti-Fct RI src=https:reader042fdocumentsecreader042viewer20220219055bb0dfc509d3f281368bfeb4html5thumbnails1jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 2button div class=trans-image a href=https:reader042fdocumentsecreader042viewer20220219055bb0dfc509d3f281368bfeb4html5page2jpg target=_blank amp-img class=trans-thumb alt=Page 2: · Conectivopatías lupus eritematoso Procesos linfoproliferativos Presencia autoanticuerpos 30-70%: Antitiroideos Antinucleares Anti-lgE anti-Fct RI src=https:reader042fdocumentsecreader042viewer20220219055bb0dfc509d3f281368bfeb4html5thumbnails2jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 3button div class=trans-image a href=https:reader042fdocumentsecreader042viewer20220219055bb0dfc509d3f281368bfeb4html5page3jpg target=_blank amp-img class=trans-thumb alt=Page 3: · Conectivopatías lupus eritematoso Procesos linfoproliferativos Presencia autoanticuerpos 30-70%: Antitiroideos Antinucleares Anti-lgE anti-Fct RI src=https:reader042fdocumentsecreader042viewer20220219055bb0dfc509d3f281368bfeb4html5thumbnails3jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 4button div class=trans-image a href=https:reader042fdocumentsecreader042viewer20220219055bb0dfc509d3f281368bfeb4html5page4jpg target=_blank amp-img class=trans-thumb alt=Page 4: · Conectivopatías lupus eritematoso Procesos linfoproliferativos Presencia autoanticuerpos 30-70%: Antitiroideos Antinucleares Anti-lgE anti-Fct RI...